Israel

Neoadjuvant Darovasertib in Primary Uveal Melanoma – NCT07015190

OptimUM-10 – Darovasertib before treatment for primary uveal melanoma Phase: Phase 3Trial ID: NCT07015190Treatment: DarovasertibStage: Primary uveal melanoma – the cancer must not have spread to other parts of the bodyUK locations: University College London Hospital and The Clatterbridge Cancer Centre, Liverpool What is this trial looking at? OptimUM-10 is investigating whether giving a drug called darovasertib before the usual treatment

Neoadjuvant Darovasertib in Primary Uveal Melanoma – NCT07015190 Read More »

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass) – NCT06007690

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass) – NCT06007690 Read More »

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma – NCT05987332

This Phase 1/2 multi-centre, open-label basket study aims to assess the safety and effectiveness of IDE196 in treating solid tumours with specific genetic changes, such as GNAQ or GNA11 mutations or PRKC fusions. The study includes patients with metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other types of solid tumours.

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma – NCT05987332 Read More »